...for new and generic drugs are demonstrating the progress and the remaining challenges in building a stronger QbD foundation for the CMC review process. With one application cleared and several more under review in the NDA pilot, experience is now growing on how to shape a QbD-based filing from which more regulatory flexibility can flow. How detailed the QbD information should be and how to design a regulatory agreement that will clarify the ongoing commitments are among the issues generating discussion as the NDA pilot proceeds. The Office of Generic Drugs is also digesting the initial positive experience with its question-based review initiative integrating QbD principles into the ANDA review process. [An update on the NDA CMC pilot program by Office of New Drug Quality Assessment official Chi-wan Chen at the DIA annual meeting in late June and summaries by industry participants of their firms’ experience with the NDA and ANDA initiatives are included.]
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.